AstraZeneca reports results from trial of combination therapy for prostate cancer
UK-based pharmaceutical company AstraZeneca has reported positive results from its Phase III CAPItello-281 trial, which evaluated Truqap combined with abiraterone and androgen deprivation therapy (ADT) for prostate cancer. Truqap showed improvement in …